Abstract:
Aim of this study was to evaluate the influence of Nebivolol, a beta-receptorblocker with additional NO-releasing abilities, on hemodynamic changes, quality of life and medical tolerance on 12 patients with chronic heartfailure NYHA class II and III. Patients all had basetherapy with glycoside, ACE-inhibitor and diuretic. Study was placebo controlled, randomised and double-blind. Results were evaluated from rightheart catheterization, 24h.urine collection and standardized questionaires.Dosetitration was fast and without worsening of heartfailure. Sideeffects were in the usual rangs without significant differences between groups. Stessheartrate, diastolic bloodpressure were significantly reduced and and performance level were significantly raised in the Nebivololgroup compare to the placebogroup. Peripheral resistance decreases while strokevolume and pulmonalcapillary wedge pressure increases during stress. Proteinexcretion raises while albumin-, sodium and potassiumexcretion decrease in the Nebivololgroup. Heartfailure symptoms don´t differ between groups and quality of life stays on close level. Overall the study showed a reasonable performance for Nebivolol in heartfailure therapy. Bigger studies need to get into details and look closer on the statistics.